Vertaling van "broadening access to medicines " (Nederlands → Frans) :

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

Regulatory approvals, if achieved, would broaden access to affordable, highquality respiratory medicines and further reinforce Sandoz's position as a leader in differentiated generics.
Les autorisations réglementaires, si elles étaient obtenues, élargiraient l’accès à des médicaments respiratoires abordables et de grande qualité, en renforçant la position de Sandoz en tant que leader des génériques différenciés.

Treatments worth USD 1.5 billion were contributed through Novartis access-to-medicine programs in 2009, reaching 79.5 million patients in need.
En 2009, Novartis a fourni pour USD 1,5 milliard de traitements par l’intermédiaire de ses programmes d’accès aux médicaments qui ont atteint 79,5 millions de patients dans le besoin.

Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales
Les programmes d’accès aux médicaments, qui comprennent des traitements contre le paludisme et la lèpre ont touché 80 millions de malades en 2009 avec des contributions s’élevant à USD 1,5 milliard soit 3% des ventes

However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.
However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

Goals of these investments: (1) Accelerate the Oncology pipeline, including faster expansion into new indications; (2) accelerate growth in targeted emerging markets by building up commercial organizations; and (3) accelerate and broaden indications for 13 major pipeline projects in General Medicines.
Les objectifs de ces investissements sont: 1) Accélérer le développement du pipeline d’Oncologie, notamment l’extension plus rapide à de nouvelles indications; 2) Accélérer la croissance dans certains marchés émergents en édifiant des organisations commerciales; 3) Accélérer et étendre les indications de treize projets importants du pipeline de Médecine générale.

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

While close to 95% of the items on the World Health Organization’s (WHO) list of essential medicines are available at reduced, off-patent prices, more than a third of the world’s population still has no access to them.
Un seul exemple illustre ce phénomène : à l’heure actuelle, un tiers de la population mondiale reste privée des traitements médicaux de base, alors que près de 95% des articles placés par l’OMS sur sa liste des médicaments essentiels sont disponibles hors brevets, à des prix réduits.

How can we provide or improve access to our medicines, for people in both developing and developed nations?
Comment donner ou améliorer l’accès à nos médicaments, autant dans les pays développés qu’en voie de développement ?